Another study suggested cPLA2 as a potential therapeutic target for personalized therapies in glioblastoma patients, demonstrating that blood exosomes-based targeted delivery of cPLA2 siRNA and metformin, selectively targeted the tumor energy metabolism obtaining antitumor effects [31]. This evidence concerns the gene PLA2G4A and glioblastoma.